DOCSLIB.ORG

South Dakota Board of Pharmacy Wholesale Distributor Licenses; Active, in Good Standing As of 02/28/2013

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
South Dakota Board of Pharmacy Wholesale Distributor Licenses; Active, in Good Standing As of 02/28/2013 SOUTH DAKOTA BOARD OF PHARMACY WHOLESALE DISTRIBUTOR LICENSES; ACTIVE, IN GOOD STANDING AS OF 02/28/2013 FullLicense FirmName DBA Address1 Address2 City State ZIPCode Expiration Issued 600-1960 21ST CENTURY HEALTH SPECIALIST, INC 1331 MAKALOA ST #B4 HONOLULU HI 96814 12/31/2012 11/08/2011 600-1277 3M COMPANY - HEALTH CARE DIVISION dba 3M 601 22ND AVE SOUTH BROOKINGS SD 57006 12/31/2013 03/19/2007 600-1532 3M ESPE DENTAL PRODUCTS 2501 SE OTIS CORLEY DRIVE BENTONVILLE AR 72712 12/31/2013 11/17/2008 57709- 600-0107 A & B WELDING SUPPLY CO INC PO BOX 2053 914 E CHICAGO ST RAPID CITY SD 2053 12/31/2013 01/28/1992 2275 SWALLOW HILL RD BLDG 600-1484 A&Z PHARMACEUTICAL LLC 1200 PITTSBURGH PA 15220 12/31/2013 07/29/2008 600-1251 A.F. HAUSER INC 4401 E U S HWY 30 VALPARAISO IN 46383 12/31/2013 01/03/2007 600-1591 ABBOTT LABORATORIES C/O WEBER DISTRIBUTION 10850 BUSINESS DR FONTANA CA 92337 12/31/2013 03/26/2009 600-0038 ABBOTT LABORATORIES INC 100 ABBOTT PARK RD D-GS02 BLDG AP5 ABBOTT PARK IL 60064 12/31/2013 01/28/1992 600-1631 ABBOTT LABORATORIES INC C/O SHIPPERS WAREHOUSE 8901 FORNEY RD DALLAS TX 75227 12/31/2013 08/13/2009 600-1917 ABBOTT LABORATORIES INC C/O BONDED LOGISTICS 7320 STATEVILLE RD CHARLOTTE NC 28269 12/31/2013 08/12/2011 600-2125 ABBOTT LABORATORIES INC C/O QUALANEX 5605 CENTERPOINT COURT GURNEE IL 60031 12/31/2013 01/17/2013 600-1529 ABBVIE ENDOCRINOLOGY INC 1 N WAUKEGAN RD BLDG AP52 NORTH CHICAGO IL 60064 12/31/2013 11/13/2008 ABBVIE PATIENT ASSISTANCE FOUNDATION 1 N WAUKEGAN RD AP31 D- 600-1372 INC 031C NORTH CHICAGO IL 60064 12/31/2013 11/20/2007 600-2058 ABBVIE US LLC DGS02 BLDG AP5 1 N WAUKEGAN RD NORTH CHICAGO IL 60064 12/31/2013 07/19/2012 600-1737 ABO PHARMACEUTICALS 7930 ARJONS DR STE A SAN DIEGO CA 92126 12/31/2013 06/09/2010 600-1768 ABRAXIS BIOSCIENCE LLC 2045 NORTH CORNELL AVENUE MELROSE PARK IL 60160 12/31/2013 07/30/2010 380 INTERLOCKEN CRESCENT, # 600-1552 ACCERA INC 780 BROOMFIELD CO 80021 12/31/2013 01/08/2009 600-1472 ACCORD HEALTHCARE INC 1009 SLATER RD STE 210B DURHAM NC 27703 12/31/2013 06/23/2008 1680 CENTURY CENTER 600-1062 ACCREDO HEALTH GROUP INC PARKWAY SUITE 8 MEMPHIS TN 38134 12/31/2013 08/18/2005 600-1547 ACE SURGICAL SUPPLY CO INC 1034 PEARL ST BROCKTON MA 02301 12/31/2013 12/22/2008 600-1966 ACME DELIVERY SERVICE INC 18101 EAST COLFAX AVENUE AURORA CO 80011 12/31/2013 11/23/2011 SOUTH DAKOTA BOARD OF PHARMACY WHOLESALE DISTRIBUTOR LICENSES; ACTIVE, IN GOOD STANDING AS OF 02/28/2013 FullLicense FirmName DBA Address1 Address2 City State ZIPCode Expiration Issued 600-1748 ACORDA THERAPEUTICS INC 420 SAW MILLRIVER ROAD ARDSLEY NY 10502 12/31/2013 07/02/2010 07207- 600-1193 ACTAVIS ELIZABETH LLC 200 ELMORA AVE ELIZABETH NJ 1106 12/31/2013 08/30/2006 600-1946 ACTAVIS INC 60 COLUMBIA ROAD; BLDG B MORRISTOWN NJ 07960 12/31/2013 10/03/2011 600-1710 ACTAVIS KADIAN LLC 60 COLUMBIA ROAD MORRISTOWN NJ 07960 12/31/2013 04/14/2010 600-1178 ACTAVIS MID ATLANTIC LLC 1877 KAWAI ROAD LINCOLNTON NC 28092 12/31/2013 07/19/2006 600-1338 ACTAVIS SOUTH ATLANTIC LLC 13800 NW 2ND ST STE 190 SUNRISE FL 33325 12/31/2013 09/14/2007 5000 SHORELINE COURT, SUITE SOUTH SAN 600-2061 ACTELION PHARMACEUTICALS US INC 200 FRANCISCO CA 94080 12/31/2013 07/23/2012 600-1697 ACTIENT PHARMACEUTICALS LLC 150 S SAUNDERS RD STE 120 LAKE FOREST IL 60045 12/31/2013 02/25/2010 600-2101 ACURA PHARMACEUTICALS INC 616 N. NORTH COURT SUITE 120 PALATINE IL 60067 12/31/2013 11/21/2012 600-1198 ADOLOR CORP 700 PENNSYLVANIA DR EXTON PA 19341 12/31/2012 08/30/2006 600-1854 ADVANCE TRAILER SYSTEMS INC dba RIVERSIDE LOGISTIC SVCS 5666 EASTPORT BLVD RICHMOND VA 23231 12/31/2013 03/11/2011 600-2111 AEGERION PHARMACEUTICALS 101 MAIN ST, 18TH FLOOR CAMBRIDGE MA 02142 12/31/2013 12/20/2012 600-1989 AFFYMAX, INC 4001 MIRANDA AVE PALO ALTO CA 94304 12/31/2013 01/19/2012 600-1661 AIDAREX PHARMACEUTICALS LLC 595 N SMITH STREET CORONA CA 92880 12/31/2013 11/03/2009 600-1359 AIR LIQUIDE INDUSTRIAL US LP 815 S MCHENRY BURLINGTON WI 53105 12/31/2013 10/12/2007 600-1360 AIR LIQUIDE INDUSTRIAL US LP 7700 WHEELER ROAD MAPLETON IL 61547 12/31/2013 10/18/2007 600-1418 AIR LIQUIDE INDUSTRIAL US LP 2915 E NUCOR RD NORFOLK NE 68702 12/31/2013 02/08/2008 61301- 600-1369 AIR PRODUCTS AND CHEMICALS INC ONE CIVIC RD PO BOX 1249 LA SALLE IL 3249 12/31/2013 11/20/2007 600-1381 AIR PRODUCTS AND CHEMICALS INC 2200 MONROE ST PO BOX 695 GRANITE CITY IL 62040 12/31/2013 11/26/2007 600-1401 AIR PRODUCTS AND CHEMICALS INC 4078 HUNT ST PO BOX 668 PRYOR OK 74362 12/31/2013 01/17/2008 600-2077 AIRGAS MERCHANT GASES LLC 309 SENTRY DR WAUKESHA WI 53186 12/31/2013 09/11/2012 SOUTH DAKOTA BOARD OF PHARMACY WHOLESALE DISTRIBUTOR LICENSES; ACTIVE, IN GOOD STANDING AS OF 02/28/2013 FullLicense FirmName DBA Address1 Address2 City State ZIPCode Expiration Issued 600-1822 AIRGAS MERCHANT GASES, LLC 4802 PFLAUM RD MADISON WI 53718 12/31/2013 12/23/2010 600-1836 AIRGAS MERCHANT GASES, LLC 410 S CREEKVIEW DR ANKENY IA 50021 12/31/2013 02/04/2011 600-0627 AIRGAS USA LLC 1420 E BENSON RD SIOUX FALLS SD 57104 12/31/2013 12/08/2000 2700 BOULEVARD OF 600-0864 AIRGAS USA LLC CHAMPIONS SIOUX CITY IA 51111 12/31/2013 06/30/2003 600-1694 AIRGAS USA LLC 1601 NICHOLAS BLVD ELK GROVE VILLAGE IL 60007 12/31/2013 02/04/2010 600-0358 AKORN INC 150 SOUTH WYCKLES ROAD DECATUR IL 62522 12/31/2013 07/25/1996 600-0472 AKORN INC 5605 CENTERPOINT CT SUITE B GURNEE IL 60031 12/31/2013 09/28/1998 600-1432 AKRIMAX PHARMACEUTICALS LLC 4580 MENDENHALL RD MEMPHIS TN 38141 12/31/2013 03/17/2008 600-0126 ALCON LABORATORIES INC 6500 WILL ROGERS BLVD FT WORTH TX 76134 12/31/2013 02/18/1992 600-1922 ALCON LABORATORIES INC 6740 BUSINESS PARKWAY ELKRIDGE MD 21075 12/31/2013 08/17/2011 600-1269 ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE CHESHIRE CT 06410 12/31/2013 02/22/2007 600-1844 ALIMERA SCIENCES INC 6120 WINDWARD PKWY STE 290 ALPHARETTA GA 30005 12/31/2013 02/15/2011 600-1603 ALK-ABELLO INC 35 CHANNEL DR PORT WASHINGTON NY 11050 12/31/2013 04/27/2009 600-1610 ALK-ABELLO INC 1700 ROYSTON LN ROUND ROCK TX 78664 12/31/2013 05/22/2009 600-1565 ALKERMES INC 265 OLINGER CIRCLE WILMINGTON OH 45177 12/31/2013 02/02/2009 600-2142 ALLEGIS PHARMACEUTICALS LLC 276 NISSAN PARKWAY F100 CANTON MS 39046 12/31/2013 02/21/2013 600-2025 ALLERGY LABORATORIES INC 1005 SW 2ND STREET OKLAHOMA CITY OK 73109 12/31/2013 04/04/2012 600-1865 ALMATICA PHARMA INC 10 BLOOMFIELD AVENUE PINE BROOK NJ 07058 12/31/2013 04/05/2011 600-1962 ALPINE HEALTH, LLC 601 PENHORN AVENUE, UNIT #1 SECAUCUS NJ 07094 12/31/2013 11/17/2011 600-1706 ALVOGEN INC 10 BLOOMFIELD AVENUE BUILDING B, SUITE 2 PINE BROOK NJ 07058 12/31/2013 03/26/2010 600-1979 ALZA CORPORATION 700 EUBANKS DRIVE VACAVILLE CA 95688 12/31/2013 12/16/2011 SOUTH DAKOTA BOARD OF PHARMACY WHOLESALE DISTRIBUTOR LICENSES; ACTIVE, IN GOOD STANDING AS OF 02/28/2013 FullLicense FirmName DBA Address1 Address2 City State ZIPCode Expiration Issued 600-1518 AMAG PHARMACEUTICALS INC 61 MOONEY STREET CAMBRIDGE MA 02138 12/31/2013 10/10/2008 600-2035 AMARIN PHARMA, INC 1430 ROUTE 206, SUITE 200 BEDMINSTER NJ 07921 12/31/2013 05/09/2012 600-1862 AMATHEON INC 4300 SW 73RD AVE STE 110 MIAMI FL 33155 12/31/2013 04/04/2011 2 WALNUT GROVE DRIVE, SUITE 600-2104 AMEDRA PHARMACEUTICALS LLC 190 HORSHAM PA 19044 12/31/2013 11/29/2012 2550 JOHN GLENN AVENUE, 600-0379 AMERICAN HEALTH PACKAGING SUITE A COLUMBUS OH 43217 12/31/2013 01/22/1997 600-0567 AMERICAN HOMEPATIENT 3231 GORDON DR SIOUX CITY IA 51105 12/31/2013 03/21/2000 600-0413 AMERICAN REGENT INC PO BOX 9001 ONE LUITPOLD DRIVE SHIRLEY NY 11967 12/31/2013 10/17/1997 600-1416 AMERICARES FOUNDATION 88 HAMILTON AVE STAMFORD CT 06902 12/31/2013 01/31/2008 600-1289 AMERIDOSE LLC 201 FLANDERS RD WESTBOROUGH MA 01581 12/31/2012 05/08/2007 600-1611 AMERIDOSE LLC 205 FLANDERS RD WESTBOROUGH MA 01581 12/31/2012 06/09/2009 600-1595 AMERIGEN PHARMACEUTICALS, INC 9 POLITO AVENUE, SUITE #900 LYNDHURST NJ 07071 12/31/2013 04/16/2009 600-1151 AMERIPHARM INC dba MEDVANTX INC 2503 E 54TH ST N SIOUX FALLS SD 57104 12/31/2013 05/08/2006 AMERISOURCE BERGEN DRUG 11200 NORTH CONGRESS 600-1052 CORPORATION AVENUE KANSAS CITY MO 64153 12/31/2013 07/12/2005 600-0825 AMERISOURCEBERGEN DRUG CORP 501 W 44TH AVE DENVER CO 80216 12/31/2013 01/07/2003 AMERISOURCEBERGEN DRUG 600-0234 CORPORATION 6810 SHADY OAK RD EDEN PRAIRIE MN 55344 12/31/2013 04/08/1993 AMERISOURCEBERGEN DRUG 600-1167 CORPORATION 6305 LASALLE DRIVE LOCKBOURNE OH 43137 12/31/2013 05/25/2006 AMERISOURCEBERGEN DRUG 600-1758 CORPORATION 5100 JAINDL BOULEVARD BETHLEHEM PA 19087 12/31/2013 07/02/2010 AMERISOURCEBERGEN DRUG 600-1794 CORPORATION 1325 WEST STRIKER AVE SACRAMENTO CA 95834 12/31/2012 11/05/2010 AMERISOURCEBERGEN DRUG 600-1948 CORPORATION 1001 W TAYLOR ROAD ROMEOVILLE IL 60446 12/31/2013 10/07/2011 AMERISOURCEBERGEN DRUG 600-2047 CORPORATION 100 FRIARS BOULEVARD THOROFARE NJ 08086 12/31/2013 06/06/2012 600-0348 AMGEN INC ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 12/31/2013 03/11/1996 SOUTH DAKOTA BOARD OF PHARMACY WHOLESALE DISTRIBUTOR LICENSES; ACTIVE, IN GOOD STANDING AS OF 02/28/2013 FullLicense FirmName DBA Address1 Address2 City State ZIPCode Expiration Issued 600-0936 AMGEN USA INC 12000 PLANTSIDE DRIVE LOUISVILLE KY 40299 12/31/2013 04/09/2004 600-1755 AMGEN USA, INC ROAD 31 KM 24.
Load more

Recommended publications
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • Other Statutory Disclosures Continued
    Other statutory disclosures continued Strategic reportGroup companies Governance & remuneration Financial statements In accordance with Section 409 of the Companies Act 2006 a full list of subsidiaries, associates, joint ventures and joint arrangements, the country of incorporation and effective percentage of equity owned, as at 31 December 2015 are disclosed below. Unless otherwise stated the share capital disclosed comprises ordinary shares which are indirectly held by GlaxoSmithKline plc. All subsidiary companies are resident for tax purposes in their country of incorporation unless otherwise stated. Country of Effective % % Held by Name incorporation Ownership Security Class of Share Wholly owned subsidiaries 1506369 Alberta ULC Canada 100 Common 100 Action Potential Venture Capital Limited England & Wales 100 Ordinary 100 Adechsa GmbH Switzerland 100 Ordinary 100 Affymax Research Institute United States 100 Common 100 Alenfarma – Especialidades Farmaceuticas, Limitada (iv) Portugal 100 Ordinary Quota 100 Allen & Hanburys Limited (iv) England & Wales 100 Ordinary 100 Allen & Hanburys Pharmaceutical Nigeria Limited Nigeria 100 Ordinary 100 Allen Farmaceutica, S.A. Spain 100 Ordinary 100 Allen Pharmazeutika Gesellschaft m.b.H. Austria 100 Ordinary 100 Aners S.A (iv) Argentina 100 Non-endorsable Nominative Ordinary 100 Barrier Therapeutics, Inc. United States 100 Common 100 Beecham Group p l c England & Wales 100 20p Shares 'A'; 5p Shares B 100 Beecham Pharmaceuticals (Pte) Limited Singapore 100 Ordinary 100 Beecham Pharmaceuticals S.A (iv) (vi) Ecuador 100 Nominative 100 Beecham Portuguesa-Produtos Farmaceuticos e Quimicos, Lda Portugal 100 Ordinary Quota 100 Beecham S.A. (iv) Belgium 100 Ordinary 100 Biddle Sawyer Limited India 100 Equity 100 Biovesta Ilaçlari Ltd. Sti. Turkey 100 Nominative 100 Burroughs Wellcome & Co (Australia) Pty Limited (iv) (vi) Australia 100 Ordinary 100 Burroughs Wellcome & Co (Bangladesh) Limited Bangladesh 100 Ordinary 100 Burroughs Wellcome International Limited England & Wales 100 Ordinary 100 Caribbean Chemical Company, Ltd.
    [Show full text]
  • Clinical Guidelines for Use of Depot Buprenorphine (Buvidal®
    Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence NSW Ministry of Health 100 Christie Street ST LEONARDS NSW 2065 Tel. (02) 9391 9000 Fax. (02) 9391 9101 TTY. (02) 9391 9900 www.health.nsw.gov.au Produced by: NSW Ministry of Health Lintzeris N, Dunlop A, Masters D (2019) Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. NSW Ministry of Health, Sydney Australia This work is copyright. It may be reproduced in whole or in part for study or training purposes subject to the inclusion of an acknowledgement of the source. It may not be reproduced for commercial usage or sale. Reproduction for purposes other than those indicated above requires written permission from the NSW Ministry of Health. © NSW Ministry of Health 2019 SHPN (CPH) 190431 ISBN 978-1-76081-226-3 Further copies of this document can be downloaded from the NSW Health website www.health.nsw.gov.au August 2019 ii NSW Health Use of depot BPN in the treatment of opioid dependence Authors Professor Nicholas Lintzeris (BMedSci MBBS PhD FAChAM) Director Drug and Alcohol Services, South East Sydney Local Health District Discipline Addiction Medicine, Faculty of Medicine and Health Sciences, University of Sydney NSW Drug and Alcohol Clinical Research and Improvement Network Professor Adrian Dunlop (MBBS, PhD, GdipEpiBiotat, FAChAM) Director Drug and Alcohol Clinical Services, Hunter New England Local Health District School of Medicine and Public Health, Faculty
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • Annual Report 2008 Find out More About GSK Online…
    Do more, feel better, live longer Grow Deliver Simplify Annual Report 2008 Find out more about GSK online… www.gsk.com Website GlaxoSmithKline’s website www.gsk.com gives additional information on the Group. Information made available on the website does not constitute part of this Annual Report. Notice regarding limitations on Director liability under English Law Under the UK Companies Act 2006, a safe harbour limits the liability of Directors in respect of statements in and omissions from the Report of the Directors contained on pages 12 to 98. Under English law the Directors would be liable to the company (but not to any third party) if the Report of the Directors contains errors as a result of recklessness or knowing misstatement or dishonest concealment of a material fact, but would not otherwise be liable. Report of the Directors Pages 12 to 98 inclusive consist of a Report of the Directors that has been drawn up and presented in accordance with and in reliance upon English company law and the liabilities of the Directors in connection with that report shall be subject to the limitations and restrictions provided by such law. Cautionary statement regarding forward-looking statements The Group’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document and written information released, or oral statements made, to the public in the future by or on behalf of the Group, may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. A shareholder can identify these statements by the fact that they do not relate strictly to historical or current facts.
    [Show full text]
  • Glaxosmithkline Annual Report 2010
    Do more, feel better, live longer GlaxoSmithKline Annual Report 2010 Contents Business review P08–P57 Business review 2010 Performance overview 08 Research and development 10 Pipeline summary 12 Products, competition and intellectual property 14 Regulation 18 Manufacturing and supply 19 Business review World market 20 This discusses our financial and non-financial activities, GSK sales performance 21 resources, development and performance during 2010 Segment reviews 22 and outlines the factors, including the trends and the Responsible business 29 principal risks and uncertainties, which are likely to Financial review 2010 34 affect future development. Financial position and resources 41 Financial review 2009 47 Governance and remuneration Risk factors 53 This discusses our management structures and governance procedures. It also sets out the Governance and remuneration P58–P101 Governance and remuneration Governance and remuneration remuneration policies operated for our Directors and Our Board 58 Corporate Executive Team members. Our Corporate Executive Team 60 Governance and policy 64 Financial statements Dialogue with shareholders 69 The financial statements provide a summary of the Internal control framework 71 Group’s financial performance throughout 2010 and its Committee reports 74 position as at 31st December 2010. The consolidated Remuneration policy 84 financial statements are prepared in accordance with Director terms and conditions 91 IFRS as adopted by the European Union and also IFRS as Director and Senior Management remuneration 94 issued by the International Accounting Standards Board. Directors’ interests 96 Directors’ interests in contracts 101 Shareholder information This includes the full product development pipeline and discusses shareholder return in the form of dividends and share price movements.
    [Show full text]
  • Other Statutory Disclosures Continued
    272 GSK Annual Report 2016 Other statutory disclosures continued Group companies In accordance with Section 409 of the Companies Act 2006 a full list of subsidiaries, associates, joint ventures and joint arrangements, the address of the registered office and effective percentage of equity owned, as at 31 December 2016 are disclosed below. Unless otherwise stated the share capital disclosed comprises ordinary shares which are indirectly held by GlaxoSmithKline plc. The percentage held by class of share is stated where this is less than 100%. Unless otherwise stated, all subsidiary companies have their registered office in their country of incorporation. All subsidiary companies are resident for tax purposes in their country of incorporation unless otherwise stated. Name Security Registered address Wholly owned subsidiaries 1506369 Alberta ULC Common 3500 855-2nd Street SW, Calgary, AB, T2P 4J8, Canada Action Potential Venture Capital Limited Ordinary 980 Great West Road, Brentford, Middlesex, TW8 9GS, England Adechsa GmbH (iv) Ordinary c/o PRV Provides Treuhandgesellschaft AG, Dorfstrasse 38, Baar, 6341, Switzerland Affymax Research Institute Common Corporation Service Company, 2710 Gateway Oaks Drive, Suite 150N, Sacramento, California, CA, 95833, United States Alenfarma – Especialidades Farmaceuticas, Ordinary Quota Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, Limitada (iv) 1495-131, Portugal Allen & Hanburys Limited (iv) Ordinary 980 Great West Road, Brentford, Middlesex, TW8 9GS, England Allen & Hanburys Pharmaceutical Nigeria Limited Ordinary 24 Abimbola Way, Ilasamaja, Isolo, Lagos, Nigeria Allen Farmaceutica, S.A. Ordinary Severo Ochoa, 2, Parque Tecnologico de Madrid, Tres Cantos, Madrid, 28760, Spain Allen Pharmazeutika Gesellschaft m.b.H. Ordinary Wagenseilgasse 3, Euro Plaza, Gebäude I, 4.
    [Show full text]
  • Mechanisms of Cocaine Abuse and Toxicity
    Mechanisms of Cocaine Abuse and Toxicity U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration I Mechanisms of Cocaine Abuse and Toxicity Editors: Doris Clouet, Ph.D. Khursheed Asghar, Ph.D. Roger Brown, Ph.D. Division of Preclinical Research National Institute on Drug Abuse NIDA Research Monograph 88 1988 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. MARY L. JACOBSON Temple University School of Medicine National Federation of Parents for Philadelphia,Pennsylvania Drug-Free Youth Omaha, Nebraska SYDNEY ARCHER, Ph.D. Rensselaer Polytechnic lnstitute Troy, New York REESE T. JONES, M.D. Langley Porter Neuropsychiatric lnstitute RICHARD E. BELLEVILLE, Ph.D. San Francisco, California NB Associates, Health Sciences RockviIle, Maryland DENISE KANDEL, Ph.D. KARST J. BESTEMAN College of Physicians and Surgeons of Alcohol and Drug Problems Association Columbia University of North America New York, New York Washington, D.C. GILBERT J.
    [Show full text]
  • Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG
    EN Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 11/01/2001 Also available in the CELEX database Document No 301M2192 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 11.01.2001 SG(2000)D/285020 In the published version of this decision, some PUBLIC VERSION information has been omitted pursuant to Article 17(2) of Council Regulation (EEC) No 4064/89 concerning non-disclosure of business secrets and other confidential information. The omissions are MERGER PROCEDURE shown thus […]. Where possible the information ARTICLE 6(1)(b) DECISION omitted has been replaced by ranges of figures or a general description. To the notifying party Dear Sir/Madam, Subject: Case No COMP/M.2192 – SmithKline Beecham/Block Drug Notification of 17.11.2000 pursuant to Article 4 of Council Regulation No 4064/89 1. On 17 November, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (“the Merger Regulation”), by which the UK company, SmithKline Beecham plc (“SB”) notified its intention to acquire sole control over the US company, Block Drug Company Inc. (“Block Drug”), through purchase of shares. 2. Following examination of the notification, the Commission has concluded that the notified operation falls within the scope of the said Council Regulation and does not raise serious doubts as to its compatibility with the common market and the EEA agreement.
    [Show full text]
  • UR-Coeus Sponsor List
    UR-Coeus Sponsor Table (alphabetical by sponsor name) Sponsor Sponsor Code Sponsor Type 2138 21st Century Medicine CORP Sponsor Type Key 1 3M CORP CORP = Corporate 3803 4S3 Bioscience Inc CORP FED = Federal 5207 A. F. Associates Family Medicine ONFA FND = Foundation 2602 A. P. Pharma CORP IND = Individuals 2 A.L. Mailman Foundation FND NYS = New York State 2023 AA Implant Dentistry Research Foundation ONFA OLG = Other Local Gov't 3 AAA Fnd for Traffic Safety ONFA ONFA = Other Non-Fed Agency 2329 aaiPharma Inc CORP VHA = Voluntary Health Agency 3257 Aamjiwnaang First Nations Community ONFA 5345 Aarhus University Hospital ONFA 3713 Aaron Copland Fund for Music, Inc. ONFA 4 AARP Andrus Fdn FND 3853 AB Sciences CORP 3378 AB Vector, Inc CORP 899 Abbott Diagnostics CORP 3864 Abbott Fund FND 14 Abbott Laboratories CORP 5126 AbbVie, Inc. CORP 5854 Abeona Therapeutics CORP 5063 Abington Medical Specialists ONFA 5331 Abington Memorial Hospital ONFA 2835 ABIOMED, Inc. CORP 3687 Ablation Frontiers CORP 5118 Ablynx NV CORP 2053 ABMRF/Fnd for Alcohol Research ONFA 2171 Abortion Rights Mobilization ONFA 3361 Abraxix BioScience, LLC CORP 4953 Abt Associates, Inc. CORP 5037 Academic Gastrointestinal Cancer Consortium ONFA 15 Academic Med Ctr Cons ONFA 3733 Academic Pediatric Association ONFA 3160 Academy of Orofacial Pain ONFA 2122 Academy of Prosthodontics Foundation ONFA 3663 Acadia Pharmaceuticals, Inc. CORP 3273 Accelerate Brain Cancer Cure ONFA 5584 Acceleron Pharma Inc. CORP 5601 Accelovance, Inc. CORP 5940 Accreditation Council Grad Med Educ ONFA 5832 Accriva Diagnostics CORP 3888 AccuGenomics, Inc. CORP 5656 Acerta Pharma CORP 6101 Acessa Health, Inc.
    [Show full text]
  • Group Companies
    Strategic report Governance and remuneration Financial statements Investor information Other statutory disclosures continued Group companies In accordance with Section 409 of the Companies Act 2006 a full list of subsidiaries, associates, joint ventures and joint arrangements, the address of the registered office and effective percentage of equity owned, as at 31 December 2019 are disclosed below. Unless otherwise stated the share capital disclosed comprises Ordinary shares which are indirectly held by GlaxoSmithKline plc. The percentage held by class of share is stated where this is less than 100%. Unless otherwise stated, all subsidiary companies have their registered office and are tax resident in their country of incorporation. Name Security Registered address Wholly owned subsidiaries 1506369 Alberta ULC Common 3500 855-2nd Street SW, Calgary, AB, T2P 4J8, Canada Action Potential Venture Capital Limited Ordinary 980 Great West Road, Brentford, Middlesex, TW8 9GS, England Adechsa GmbH (ii) Ordinary c/o PRV Provides Treuhandgesellschaft AG, Dorfstrasse 38, Baar, 6341, Switzerland Affymax Research Institute Common Corporation Service Company, 2710 Gateway Oaks Drive, Suite 150N, Sacramento, California, 95833, United States Alenfarma – Especialidades Farmaceuticas, Limitada (ii) Ordinary Quota Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, 1495-131, Portugal Allen & Hanburys Limited (ii) Ordinary 980 Great West Road, Brentford, Middlesex, TW8 9GS, England Allen & Hanburys Pharmaceutical Nigeria Limited Ordinary 24 Abimbola Way, Ilasamaja, Isolo, Lagos, Nigeria Allen Farmaceutica, S.A. Ordinary Severo Ochoa, 2, Parque Tecnologico de Madrid, Tres Cantos, Madrid, 28760, Spain Allen Pharmazeutika Gesellschaft m.b.H. Ordinary Wagenseilgasse 3, Euro Plaza, Gebäude I, 4. Stock, Vienna, A-1120, Austria Barrier Therapeutics, Inc.
    [Show full text]